Drug Details
General Information of the Drug (ID: DR3524) | ||||
---|---|---|---|---|
Name |
Lithium chloride
|
|||
Synonyms |
LITHIUM CHLORIDE; 7447-41-8; Lithium chloride (LiCl); Lithiumchloride; LiCl; chlorolithium; chlorure de lithium; MFCD00011078; Lithium Cholride; UNII-G4962QA067; CHEBI:48607; CHEMBL69710; Chlorku litu; NSC327172; G4962QA067; Lithiumchlorid; Lithium Chloride, Anhydrous; Lithium chloride, ultra dry; Chlorku litu [Polish]; Lithium chloride, 99%, extra pure; Luthium chloride; ClLi; Lithium chloride, 99+%, ACS reagent; Chlorure de lithium [French]; CCRIS 5924; Lithium chloride, 99%, for molecular biology; HSDB 4281; Lithium chloride, 99%, for analysis, anhydrous; Lithium chloride solution; EINECS 231-212-3; lithium(1+) ion chloride; NSC 327172; Lithium Chloride (2.3% in Tetrahydrofuran, ca. 0.5mol/L); lithim chloride; lithii chloridum; lithium;chloride; Lithium chloride, anhydrous, chunks, 99.99% trace metals basis; cloruro de litio; Lithium Chloride Salt; Lopac-L-4408; Lithium chloride (powder); MolMap_000071; WLN: LI G; EC 231-212-3; LithiumChlorideGr(Anhydrous); Lithium chloride, ACS grade; Lopac0_000604; Lithium chloride battery grade; Lithium chloride 1 M solution; Lithium chloride, ACS reagent; DTXSID2025509; Lithium chloride, 3-5% in THF; HMS3261J10; Tox21_500604; ANW-36491; BDBM50494542; AKOS015902822; AKOS015950647; AKOS024438070; Lithium chloride, 1M aqueous solution; CCG-204693; lithium chloride, gamma irradiated, 8m; LP00604; NSC-327172; SDCCGSBI-0050586.P002; Lithium chloride, ACS reagent, >=99%; Lithium chloride, ReagentPlus(R), 99%; NCGC00015607-01; NCGC00015607-02; NCGC00015607-03; NCGC00015607-04; NCGC00015607-07; NCGC00093980-01; NCGC00093980-02; NCGC00261289-01; AK323906; BP-13612; Lithium chloride, 200mM aqueous solution; SY002997; Lithium chloride solution, 1 M in ethanol; Lithium chloride solution, 2 M in ethanol; Lithium chloride, Vetec(TM) reagent grade; EU-0100604; FT-0627896; L0204; L0222; Lithium chloride, Trace metals grade 99.9%; W8215; L 4408; Lithium chloride, SAJ first grade, >=98.0%; Lithium chloride, for molecular biology, >=99%; Lithium chloride, SAJ special grade, >=99.0%; A838146; Lithium chloride, BioXtra, >=99.0% (titration); Q422930; SR-01000076252; SR-01000076252-1; Electrolyte solution, nonaqueous, 2 M LiCl in ethanol; Lithium chloride solution, 1 M in glacial acetic acid; Lithium chloride, powder, >=99.99% trace metals basis; Z1741960146; Electrolyte solution, nonaqueous, LiCl in ethanol (saturated); Lithium chloride solution, 0.5 M in anhydrous tetrahydrofuran; Lithium chloride solution, 8 M, for molecular biology, >=99%; Lithium chloride, puriss. p.a., anhydrous, >=99.0% (AT); Lithium chloride solution, 1 M in 1,3-dimethyl-2-imidazolidinone; Lithium chloride, anhydrous, beads, -10 mesh, >=99.9% trace metals basis; Lithium chloride, anhydrous, beads, -10 mesh, 99.998% trace metals basis; Lithium chloride, puriss. p.a., ACS reagent, anhydrous, >=99.0% (AT); Lithium chloride, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; Lithium chloride, anhydrous, free-flowing, Redi-Dri(TM), ReagentPlus(R), 99%; Lithium chloride, BioUltra, for molecular biology, anhydrous, >=99.0% (AT); Lithium atomic spectroscopy standard concentrate 1.00 g Li, 1.00 g/L, for 1 l standard solution, analytical standard; Lithium standard solution, suitable for atomic absorption spectrometry, 1 mg/mL Li, 1000 ppm Li
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Multiple myeloma [ICD-11: 2A83] | Investigative | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
ClLi
|
|||
PubChem CID | ||||
Canonical SMILES |
[Li+].[Cl-]
|
|||
InChI |
1S/ClH.Li/h1H;/q;+1/p-1
|
|||
InChIKey |
KWGKDLIKAYFUFQ-UHFFFAOYSA-M
|
|||
CAS Number |
CAS 7447-41-8
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Phosphorylation | GSK-3B | Molecule Info |
Pathway MAP
|
||
In-vitro Model | RD | CVCL_1649 | Embryonal rhabdomyosarcoma | Homo sapiens | ||
Rh30 | CVCL_0041 | Alveolar rhabdomyosarcoma | Homo sapiens | |||
Experimental
Result(s) |
Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Glycogen synthase kinase-3 alpha (GSK-3A) | Molecule Info | [3] | |
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | Click to Show/Hide | ||
2 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
3 | PDGF signaling pathway | |||
4 | Ras Pathway | |||
Pathway Interaction Database | Degradation of beta catenin | Click to Show/Hide | ||
2 | Canonical Wnt signaling pathway | |||
3 | FOXM1 transcription factor network | |||
4 | Class I PI3K signaling events mediated by Akt | |||
Reactome | AKT phosphorylates targets in the cytosol | Click to Show/Hide | ||
2 | XBP1(S) activates chaperone genes | |||
3 | Constitutive Signaling by AKT1 E17K in Cancer |

